Ionis Pharmaceuticals (MEX:IONS) Total Current Assets: MXN52,961 Mil (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
65 GF Score
Price MXN1,150.00
GF Value MXN782.91
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Total Current Assets?

Ionis Pharmaceuticals MEX:IONS 65 Total Current Assets is MXN52,961 Mil as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 65/100 and a GF Value™ of MXN782.91. The stock has 8 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Ionis Pharmaceuticals's total current assets for the quarter that ended in Mar. 2026 was MXN52,961 Mil.


Ionis Pharmaceuticals  (MEX:IONS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Ionis Pharmaceuticals's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=34606.789-53350.735+0.75 * 0+0.5 * 100.208
=-18,694

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ionis Pharmaceuticals Total Current Assets Related Terms


Ionis Pharmaceuticals Total Current Assets Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Total Current Assets Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48,106.34 42,943.72 44,843.47 54,647.98 53,848.48

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49,487.00 48,525.67 46,208.91 53,848.48 52,961.05
MEX:IONS
65GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Ionis Pharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Ionis Pharmaceuticals's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of MXN52,961 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Total Current Assets of MXN52,961 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Total Current Assets too high?
Ionis Pharmaceuticals' current Total Current Assets is MXN52,961 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Total Current Assets compare to EXEL and BBIO?
Ionis Pharmaceuticals' Total Current Assets of MXN52,961 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Total Current Assets is MXN52,961 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Total Current Assets of MXN52,961 Mil. The stock's GF Value™ is MXN782.91, compared to a current price of MXN1,150.00 — trading 46.9% above its estimated fair value. The current Total Current Assets is MXN52,961 Mil. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Total Current Assets is MXN52,961 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 46.9% above its estimated GF Value™ of MXN782.91.

Key valuation signals for MEX:IONS:

  • Total Current Assets: MXN52,961 Mil
  • GF Value™: MXN782.91 vs. price of MXN1,150.00 (46.9% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score

Get the complete analysis for MEX:IONS

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN782.91
GF Value